Signal detail

News insight

Source-backed analysis, the reasoning behind the signal, and its market context.

Back to signals Ask the Agent

DCTHBullishEarningsShort Term

High materiality9/10

Delcath Systems Reports Second Quarter 2026 Results and Business Highlights

StockNews.AIAug 6, 8:01 AM EDT1 source

Trading thesisImportance 9/10

Short-term bullish, 1–3 months, as guidance and center-network expansion unlock upside for DCTH.

AI summary

What happened and why it matters

Delcath reported Q2 2026 revenue of $29.1M, led by HEPZATO KIT at $27.1M and CHEMOSAT at $2.0M. The company raised 2026 revenue guidance to $104–$108M and maintains positive EBITDA, supported by 31 active centers and roughly 30% YoY growth in HEPZATO volume. The data underscore a potential multi-indication liver-directed therapy platform with expanding physician adoption.

Guidance increased to $104–$108M for 2026, signaling stronger revenue trajectory.
HEPZATO KIT volume growth ~28% YoY supports near-term upside.
31 active treatment centers indicate ongoing commercial expansion.
Company holds $95.9M cash, no debt, providing optionality.

Sentiment rationale

The upward revision of 2026 revenue guidance to 104–108M, strong HEPZATO KIT contribution (27.1M), and 31 active centers imply improved revenue visibility and potential margin/EBITDA progression. History shows that material guidance raises in healthcare tech/biotech equipment providers often drive multiple expansion or at least short-term upside as investors re-price growth prospects. Positive cash flow and no debt further support optionality for expansion and R&D for Phase 2 trials.

Key facts

01
Q2 2026 revenue $29.1M; HEPZATO KIT $27.1M, CHEMOSAT $2.0M.
02
Gross margins 90% vs 86% YoY.
03
2026 revenue guidance raised to $104–$108M; 28% HEPZATO KIT growth.
04
31 active centers; ~30% YoY growth in HEPZATO volume.
05
First patient dosed in HER2-negative metastatic breast cancer Phase 2.

Earnings

Category: Earnings. The release centers on quarterly results, updated full-year guidance, and ongoing clinical/corporate developments, aligning with earnings-driven coverage and near-term valuation catalysts from better-than-expected revenue trajectory and expanded treatment-center footprint.